Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
30.83 USD +1.85% Intraday chart for Supernus Pharmaceuticals, Inc. +2.53% +6.53%
Apr. 24 Supernus Pharmaceuticals, Inc. Announces Retirement of John M. Siebert from the Board of Directors CI
Apr. 08 Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
GL
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
GL
Supernus Pharmaceuticals, Inc. Announces Retirement of John M. Siebert from the Board of Directors
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready
DJ
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket
MT
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830
CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
RE
Supernus Provides Regulatory Update for SPN-830
GL
Supernus Provides Regulatory Update for SPN-830
AQ
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing
MT
Transcript : Supernus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM
Supernus to Participate in Two Upcoming Investor Conferences
GL
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
GL
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.